CorMedix

CorMedix, Inc. operates as a pharmaceutical and medical device company. The firm seeks to license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector

CorMedix Appoints Paulo Costa to its Board of Directors

BERKELEY HEIGHTS, N.J., Sept.  09, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference taking place on September 14 – 16, 2020.

CorMedix Inc. to Present at the H.C.

BERKELEY HEIGHTS, N.J., Aug.  31, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI). The FDA had previously granted a rolling submission and review, which the Company completed at the end of June.  The FDA also granted priority review and set a Prescription Drug User Fee Act (PDUFA) date of February 28, 2021 for the completion of its review for approval of the NDA.  The Agency noted that it is planning to hold an advisory committee meeting to discuss the application and that it had not identified any potential review issues at this time.

CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

CorMedix (CRMD) Jumps: Stock Rises 9.8%

CorMedix's (CRMD) CEO Khoso Baluch on Q2 2020 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

CorMedix Inc. Reports Second Quarter and Six Month 2020 Financial Results and Provides Business Update

Cormedix (AMEX: CRMD) unveils its next round of earnings this Monday, August 10.

Cormedix's Earnings: A Preview

BERKELEY HEIGHTS, N.J., Aug.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Monday, August 10, and will host a corporate update conference call at 4:30pm Eastern Time.

CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10

BERKELEY HEIGHTS, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has priced its underwritten public offering of 4,444,444 shares of its common stock at $4.50 per share for total gross proceeds, before underwriting commissions and estimated expenses, of approximately $20 million. In connection with the offering, the Company granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock.  The offering is expected to close on July 30, 2020, subject to customary closing conditions.    

CorMedix Announces Pricing of $20M Public Offering of Common Stock

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

CorMedix (CRMD) Jumps: Stock Rises 7.5%

Priority Review of NDA Requested Priority Review of NDA Requested

CorMedix Inc. Reports Submission of Defencath™ New Drug Application

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates

BERKELEY HEIGHTS, N.J., May  11, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:  CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has appointed Matt David, M.D. as the Company’s Executive Vice President and Chief Financial Officer.  Dr. David will participate in the Company’s Conference Call discussing its First Quarter 2020 financial results and recent corporate developments today at 4:30pm Eastern time.

CorMedix Inc. Announces Appointment of Chief Financial Officer

BERKELEY HEIGHTS, N.J., April  23, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered into a new three-year Employment Agreement with Jack Armstrong, currently Executive Vice President and Head of Technical Operations. The new agreement terminates in April 2023, and may be extended annually thereafter upon mutual agreement. The Employment Agreement was concluded as CorMedix works to secure marketing authorization for Neutrolin® in the second half of 2020 with potential commercial launch in the U.S. in 2021.

CorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical Operations

Ardmore Shipping

Arcimoto

Ovid Therapeutics

Top Ranked Momentum Stocks to Buy for April 22nd

BERKELEY HEIGHTS, N.J., April  22, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2019. As a result, the Company has received approximately $5.2 million in cash from the sale of these NOL tax benefits.

CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program

As of late, it has definitely been a great time to be an investor CorMedix

Will CorMedix Continue to Surge Higher?

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q4 2019 Results - Earnings Call Transcript

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates

BERKELEY HEIGHTS, N.J., Feb.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved by the New Jersey Economic Development Authority (NJEDA) to transfer approximately $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program for State Fiscal Year 2019.  The Company anticipates receiving approximately $5.2 million in cash proceeds from the sale of its NOLs during the first quarter of 2020.  Closing is subject to NJEDA’s typical closing conditions, which are in process.

CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

BERKELEY HEIGHTS, N.J., Feb.  03, 2020  (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that the US Food and Drug Administration has granted the request for a rolling review of the New Drug Application (NDA) for Neutrolin® for the prevention of catheter-related blood stream infections (CRBSIs) in hemodialysis patients.  Neutrolin has received Fast Track Designation from FDA and the Company confirmed with FDA in a pre-NDA meeting that it was eligible to request a rolling review.  A rolling submission of the NDA is designed to expedite the review process for products being developed to address an unmet medical need.  CorMedix remains on schedule for a potential NDA approval during the second half of 2020.

CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q3 2019 Results - Earnings Call Transcript

News for CorMedix Stock (CRMD)